Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules

[1]  W. Couet,et al.  Tissue Distribution of Indinavir Administered as Solid Lipid Nanocapsule Formulation in mdr1a (+/+) and mdr1a (−/−) CF-1 Mice , 2005, Pharmaceutical Research.

[2]  J. Au,et al.  Formulating Paclitaxel in Nanoparticles Alters Its Disposition , 2005, Pharmaceutical Research.

[3]  D. Bazile,et al.  Influence of Lipid Nanocapsules Composition on Their Aptness to Freeze-Drying , 2005, Pharmaceutical Research.

[4]  J. Leroux,et al.  Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[5]  R. Müller,et al.  Solid lipid nanoparticles for parenteral drug delivery. , 2004, Advanced drug delivery reviews.

[6]  Youn-Chul Kim,et al.  Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  S. Benita,et al.  Enhanced Oral Absorption of Paclitaxel in a Novel Self-Microemulsifying Drug Delivery System with or Without Concomitant Use of P-Glycoprotein Inhibitors , 2004, Pharmaceutical Research.

[8]  P. Gao,et al.  Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. , 2003, Journal of pharmaceutical sciences.

[9]  アルフ、ランプレヒト,et al.  The use of p-glycoprotein inhibitor surfactants at the surface of the colloidal carrier , 2003 .

[10]  S. Feng,et al.  A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[11]  J. Schellens,et al.  Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. , 2002, The oncologist.

[12]  J. Benoit,et al.  New lipid nanocapsules exhibit sustained release properties for amiodarone. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[13]  J. Benoit,et al.  A Novel Phase Inversion-Based Process for the Preparation of Lipid Nanocarriers , 2002, Pharmaceutical Research.

[14]  D. Aggarwal,et al.  Paclitaxel and its formulations. , 2002, International journal of pharmaceutics.

[15]  T. Lecompte,et al.  In Vitro and In Vivo Evaluation of Oral Heparin–Loaded Polymeric Nanoparticles in Rabbits , 2002, Circulation.

[16]  Alex Sparreboom,et al.  Role of Formulation Vehicles in Taxane Pharmacology , 2001, Investigational New Drugs.

[17]  J. Schellens,et al.  Oral Delivery of Taxanes , 2001, Investigational New Drugs.

[18]  J. Schellens,et al.  Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  C. Porter,et al.  Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. , 2000, Journal of pharmaceutical sciences.

[20]  W. Charman,et al.  Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. , 2000, Journal of pharmaceutical sciences.

[21]  J. Schellens,et al.  Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Der,et al.  Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  J. Beijnen,et al.  Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. , 1997, British Journal of Cancer.

[24]  Morton B. Brown,et al.  Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.

[25]  H. Burt,et al.  Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. , 1997, Journal of pharmaceutical sciences.

[26]  J. Beijnen,et al.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Coon,et al.  Comparison of solutol HS 15, cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents , 1995, International journal of cancer.

[28]  K. Nicolaou,et al.  Chemistry and Biology of Taxol , 1994 .

[29]  R S Weinstein,et al.  Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. , 1991, Cancer research.

[30]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[31]  Sung-Joo Hwang,et al.  Enhanced Oral Bioavailability of Paclitaxel by Coadministration of the P-Glycoprotein Inhibitor KR30031 , 2004, Pharmaceutical Research.

[32]  Robin Hull,et al.  A good practice guide to the administration of substances and removal of blood, including routes and volumes , 2001, Journal of applied toxicology : JAT.

[33]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .

[34]  B R Goldspiel,et al.  Paclitaxel (Taxol) , 1994, Pharmacotherapy.

[35]  E. Rowinsky.  Clinical pharmacology of Taxol. , 1993, Journal of the National Cancer Institute. Monographs.

[36]  J. W. Wilson,et al.  Taxol: a history of pharmaceutical development and current pharmaceutical concerns. , 1993, Journal of the National Cancer Institute. Monographs.

[37]  B. Monsarrat,et al.  Hepatic metabolism and biliary excretion of Taxol in rats and humans. , 1993, Journal of the National Cancer Institute. Monographs.

[38]  Rowinsky Ek.  Clinical pharmacology of Taxol. , 1993 .

[39]  M. Aprahamian,et al.  Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine , 1987, Biology of the cell.